Marker Therapeutics Inc
For the period ended Dec 31, 2023. Filed Mar 26, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 26, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
| | | | | | | |
|---|---|---|---|---|---|---|
| · December 31, · December 31, | ||||||
| | 2023 | | 2022 | |||
| ASSETS | | | | | | |
| Current assets: | | | | | | |
| Cash and cash equivalents | | $15,111,450 | | $11,782,172 | ||
| Prepaid expenses and deposits | | 988,126 | | 1,849,239 | ||
| Other receivables | | | 1,027,815 | | | 2,402,004 |
| Current assets of discontinued operations | | | — | | | 585,840 |
| Total current assets | | 17,127,391 | | 16,619,255 | ||
| Non-current assets of discontinued operations | | | — | | | 17,802,929 |
| Total assets | | $17,127,391 | | $34,422,184 | ||
| | | | | | | |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | | | ||||
| Current liabilities: | | | ||||
| Accounts payable and accrued liabilities | | $1,745,193 | | $2,521,193 | ||
| Related party payable | | | 1,329,655 | | | — |
| Current liabilities of discontinued operations | | | — | | | 5,260,616 |
| Total current liabilities | | 3,074,848 | | 7,781,809 | ||
| Non-current liabilities of discontinued operations | | | — | | | 7,039,338 |
| Total liabilities | | 3,074,848 | | 14,821,147 | ||
| | | | | | | |
| Stockholders’ equity: | | | | | ||
| Preferred stock, $0.001 par value, 5 million shares authorized, 0 shares issued and outstanding at December 31, 2023 and 2022, respectively | | | — | | | — |
| Common stock, $0.001 par value, 30 million shares authorized, 8.9 million and 8.4 million shares issued and outstanding as of December 31, 2023 and 2022, respectively (see Note 10) | | | 8,891 | | | 8,406 |
| Additional paid-in capital | | 450,329,515 | | 447,641,680 | ||
| Accumulated deficit | | (436,285,863) | | (428,049,049) | ||
| Total stockholders’ equity | | 14,052,543 | | 19,601,037 | ||
| Total liabilities and stockholders’ equity | | $17,127,391 | | $34,422,184 | ||
On January 26, 2023, the Company effected a one-for-ten (1-for-10) reverse stock split of its common stock and a corresponding reduction in the total number of authorized shares of its common stock from 300,000,000 to 30,000,000. All historical share and per share amounts reflected in this report have been adjusted to reflect the reverse stock split.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.